导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.33% | 858/3712 |
| 近一周 | -0.96% | 1106/4228 |
| 近一月 | -3.27% | 1819/4196 |
| 近一季 | -7.54% | 2233/4044 |
| 近半年 | -2.70% | 1767/3824 |
| 近一年 | 11.13% | 819/3446 |
| 近两年 | 73.49% | 753/2399 |
| 近三年 | 41.28% | 566/1802 |
| 成立以来 | 192.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.19% 1019/4961 |
19.49% 1292/5312 |
- - |
- - |
| 2025 | 29.27% 1414/4813 |
1.77% 1554/3635 |
1.64% 2248/4076 |
23.23% 1561/4524 |
1.41% 1388/4813 |
| 2024 | 8.50% 1548/3463 |
-1.21% 1195/2808 |
-4.07% 1462/3014 |
14.72% 1922/3129 |
-0.21% 1345/3463 |
| 2023 | -4.13% 665/2656 |
7.62% 549/2280 |
-3.45% 798/2385 |
-2.88% 777/2515 |
-5.00% 1231/2655 |
| 2022 | -18.10% 661/2207 |
-13.62% 797/1919 |
3.19% 1196/2016 |
-10.48% 414/2113 |
2.64% 876/2208 |
| 2021 | 25.88% 107/1822 |
0.07% 319/1255 |
12.27% 340/1330 |
7.54% 180/1466 |
4.18% 358/1822 |
| 2020 | 33.77% 450/1250 |
-3.04% 283/1022 |
18.89% 317/1060 |
10.44% 547/1152 |
- - |
| 2019 | 30.50% 484/1092 |
29.35% 275/748 |
-8.27% 586/797 |
2.33% 305/844 |
7.49% 426/912 |
| 2018 | -29.48% 453/834 |
- - |
- - |
- - |
-11.21% 263/691 |
| 2017 | 4.74% 383/714 |
- - |
- - |
- - |
- - |
| 2016 | -11.17% 288/605 |
- - |
- - |
- - |
- - |
| 2015 | 46.97% 26/575 |
- - |
- - |
- - |
- - |
| 2014 | 39.66% 126/237 |
- - |
- - |
- - |
- - |
| 2013 | 17.17% 19/186 |
- - |
- - |
- - |
- - |
| 2012 | -0.55% 119/137 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中信保诚中证500指数(LOF)A VS. 长安沪深300非周期A(740101) |